Transplant Rejection Treatment Market

The transplant rejection treatment occurs when the recipient's immunosystem damages the transplanted Organs/tissue. There are mainly three types of rejections happened such as chronic rejection, acute rejection and hyperacute rejection.

Transplant rejection treatment can be done by removal of tissue, re-transplantation, gene therapy, immunosuppressive therapy, antibody-based treatments etc. Several drugs have been manufactured by many companies around the world for transplant rejection treatment. Cyclosporine is one of the best immunosuppressant available in the market, first discovered by randomized clinical trial in Europe and Canada in 1981.

The market for transplant rejection treatment is increasing day by day with an increase in number of products and drugs. Recently, a novel immunosuppressive agent FTY720 (Fingolimod) has been reported to have high efficacy and safety for the transplant rejection treatment.

There are several other FDA approved drugs available in the market such as rATG, basiliximab, alemtuzumab, muromonab-CD3 (OKT3) etc. for the transplant rejection treatment. Besides, the immunosuppressive drugs plays the major role in secure organ transplantation.

There are various companies such as Biogene Inc., Capricor Therapeutics, Inc., Cleveland BioLabs, Inc., etc. are actively developing transplant rejection treatment products for management of successful organ transplantation. However, due to inconsistency in proper organ/tissue transplantation, more opportunities are seems to be available for the market players to develop novel products for the transplant rejection treatment.

The increasing number of chronic diseases resulting the incidence of organ failure, which gives rise the organ/tissue transplantation. Complications associated with the rejection of organ/tissue transplantation drives the transplant rejection treatment market.

The increasing demand for organ transplantation among the individuals also drives the transplant rejection treatment market. Increasing consumption of alcohol and smoking habits of the youth increasing the rate of organ failure drives the transplant rejection treatment market.

However, rejection of transplant organs/tissues due to lack of potent immunosuppressive drugs and therapies as well as the appearance of various side effects restrains the transplant rejection treatment market.

The U.S. is expected as the leading market of transplant rejection treatment due to technological advancement, higher healthcare funds and demand on organ transplantation among the individuals. In Europe are also providing big budgets towards research and innovation of new technologies towards transplant rejection treatment.

However, the South Asian countries such as India and China, the opportunities to develop and sell new transplant rejection treatment products is higher due to large population and organ failure cases, which is expected to provide huge growth of the product to the market players.

Some of players operating in the transplant rejection treatment market are Biogen Inc., Cell Source, Inc., Bellicum Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cleveland BioLabs, Inc., Fate Therapeutics, Inc., Cellect Biotechnology Ltd.., F. Hoffmann-La Roche Ltd., Compugen Ltd., Escape Therapeutics, Inc., Cytodyn Inc. and others.

• Transplant Rejection Treatment Market Segments
• Transplant Rejection Treatment Market Dynamics
• Historical Actual Market Size, 2014 - 2018
• Transplant Rejection Treatment Market Size & Forecast 2019 to 2029
• Transplant Rejection Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Transplant Rejection Treatment Market Drivers and Restraints

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

• Shifting industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance